AlphAIAlphAI — Financial news for AI agents
tradingview.comSEP 231 min read$ASTH

Astrana is latest U.S. healthcare company to face acyberattack

Astrana Health ASTH fell 7% premarket after reporting a 'material' cybersecurity incident at its subsidiary, Astrana Health Management. The breach involved unauthorized access to private/confidential data via social engineering. The company is investigating and stated the incident won't materially impact its financials, as of Sept. 22.

Original reporting
tradingview.com
Published Sep 23, 2026, 1:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 1:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Astrana is latest U.S. healthcare company to face acyberattack — source image
Source · tradingview.com
Decision brief

The 30-second read

$ASTHBearishMed
01

Why it matters

The breach is material, prompting a notable pre‑market sell‑off and heightened risk perception.

02

Market read

The incident drives immediate negative sentiment and may influence broader healthcare sector risk assessments.

03

What to watch

Potential insurance coverage and limited operational disruption.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Astrana Health is a U.S. healthcare services platform; cyber incidents can affect patient data and regulatory compliance.

Company-level read

Ticker impact

$ASTHBearishHigh confidence
Context

Astrana Health reported a material cyberattack causing a >7% pre‑market drop.

Expected impact

Potential further decline of 3‑5% intraday before stabilization.

Evidence & confidence

First‑report breach, material incident, and immediate price reaction indicate heightened risk.

Market effects

Sector

Raises cybersecurity concerns for U.S. healthcare providers.

Regional

May pressure other health‑tech stocks in the U.S. market.

Global

Limited to U.S. healthcare sector.

Counterpoint

What could challenge this read

If breach impact is contained, the stock could rebound quickly.

Key entities

  • Company
    Astrana Health

    U.S. healthcare services platform reporting the breach.

Read at source← All news

Related articles

SEP 23
$ASTHMed

Why Astrana Health (ASTH) Shares Are Trading Lower Today

Astrana Health (ASTH) shares fell 5.5% after disclosing a cybersecurity incident and data breach at its subsidiary, adding to existing pressures from a securities-law investigation and Medicare regulatory concerns. The stock is volatile, down 33.3% from its 52-week high, and up 31.7% year-to-date. Investors are assessing the long-term impact of potential Medicare Advantage reforms on the company's margins.

financialcontent.com2 min
SEP 15
$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

financialcontent.com2 min
AUG 13
$ASTHMedAI 8/10

Astrana Health (ASTH) Q2 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q2 2026 revenue of $972.5M, up 49% YoY, and adjusted EBITDA of $68.9M, up 43%. Adjusted EPS was $0.80. Six-month free cash flow was $92.9M. The company reaffirmed full-year revenue guidance of $3.8B to $4.1B and raised adjusted EBITDA guidance to $255M to $280M. Net leverage was 2.26.

fool.com7 min
AUG 7
$ASTHMedAI 8/10

Astrana Health Inc (ASTH) (Q2 2026) Earnings Call Highlights: Record EPS and Raised

Astrana Health Inc (ASTH) reported Q2 2026 results with record EPS and raised guidance, according to management on its earnings call. The company cited a one-time $15 million Q2 revenue reduction tied to CMS adjustments for ACO REACH 2025 billing, with immaterial net EBITDA impact. It also discussed Medicaid membership attrition, commercial cost trends, and wide Q4 2026 EBITDA guidance of $47-$67 million.

yahoo.com4 min
AUG 6
$ASTHMed

Astrana Health (NASDAQ:ASTH) Beats Q2 CY2026 Non

Astrana Health (NASDAQ:ASTH) reported Q2 CY2026 revenue of $972.5 million, up 48.5% year on year but below market expectations. Next-quarter revenue guidance was $1.02 billion, about 1.1% under analysts’ estimates. Non-GAAP EPS was $0.80, up 9.6% versus consensus. Shares rose 5.1% to $35.89 after results.

financialcontent.com6 min